NOVABAY PHARMACEUTICALS INC (NBY) Earnings History & Surprises
NYSEARCA:NBY • US66987P4090
1.26 USD
+0.02 (+1.61%)
At close: Mar 10, 2026
1.23 USD
-0.03 (-2.38%)
Pre-Market: 3/11/2026, 8:22:31 AM
Past quarterly earnings results for NOVABAY PHARMACEUTICALS INC (NBY), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Release DateMar 31, 2026
PeriodQ1 / 2025
EPS Estimate-$0.24
Revenue Estimate3.03M
Last Reported
Release DateNov 5, 2025
PeriodQ4 / 2024
EPS Reported
EPS Surprise %
Revenue Surprise -27.48%
Beat Rate
13%
EPS and Revenuebeats vs estimates
Quarterly Earnings Results
EPS & Revenue History (USD)
Actual vs estimated values, surprises, q2q growth and acceleration numbers for recent quarters.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2024 | -0.11 | - | 99.76% | 2.309M | 3.184M | -27.48% | -38.05% | |
| Q3 2024 | -0.33 | -0.31 | -7.13% | 97.45% | 2.441M | 2.649M | -7.85% | -25.24% |
| Q2 2024 | -1.37 | -1.24 | -10.73% | 93.88% | 2.4M | 3.186M | -24.67% | -47.94% |
| Q1 2024 | -5.25 | -5.30 | 0.99% | 82.35% | 2.631M | 3.314M | -20.61% | -15.78% |
| Q4 2023 | -46.55 | -10.61 | -338.94% | -70.51% | 3.727M | 3.434M | 8.53% | 2.39% |
| Q3 2023 | -12.95 | -14.26 | 9.21% | 89.43% | 3.265M | 3.582M | -8.85% | -14.75% |
| Q2 2023 | -22.40 | -19.62 | -14.17% | 54.29% | 4.61M | 3.712M | 24.19% | 25.96% |
| Q1 2023 | -29.75 | -32.17 | 7.52% | 51.43% | 3.124M | 3.232M | -3.34% | -4.46% |
| Q4 2022 | -27.30 | -6.01 | -354.28% | -11.43% | 3.64M | 5.151M | -29.33% | 37.88% |
| Q3 2022 | -122.50 | -43.30 | -182.89% | -100.00% | 3.83M | 3.788M | 1.11% | 68.72% |
| Q2 2022 | -49.00 | -43.30 | -13.15% | - | 3.66M | 3.545M | 3.24% | 23.65% |
| Q1 2022 | -61.25 | -37.12 | -65.02% | -25.00% | 3.27M | 3.293M | -0.70% | 80.66% |
| Q4 2021 | -24.50 | -61.86 | 60.40% | 50.00% | 2.64M | 3.378M | -21.85% | 39.68% |
| Q3 2021 | -61.25 | -49.49 | -23.76% | 37.50% | 2.27M | 2.459M | -7.69% | 4.61% |
| Q2 2021 | -49.00 | -49.49 | 0.99% | 73.33% | 2.96M | 2.02M | 46.53% | -25.63% |
| Q1 2021 | -49.00 | -49.49 | 0.99% | 33.33% | 1.81M | 2.363M | -23.40% | -4.23% |
| Q4 2020 | -49.00 | -55.68 | 11.99% | - | 1.89M | 2.505M | -24.55% | - |
| Q3 2020 | -98.00 | -49.49 | -98.02% | - | 2.17M | 2.55M | -14.90% | - |
| Q2 2020 | -183.75 | -68.05 | -170.03% | - | 3.98M | 2.879M | 38.24% | - |
| Q1 2020 | -73.50 | -86.61 | 15.13% | - | 1.89M | 2.116M | -10.68% | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
N/A
Average EPS beat (4)
N/A
Max EPS beat (4)
N/A
Min EPS beat (4)
N/A
Revenue beat statistics
Revenue beat (4)
0
Average Revenue beat (4)
-20.15%
Max Revenue beat (4)
-7.85%
Min Revenue beat (4)
-27.48%
Analysis
NBY has not beaten revenue estimates in any of the last 4 earnings releases
In the last 4 quarters, NBY reported -20.2% below the revenue estimates on average.
NOVABAY PHARMACEUTICALS INC / NBY Earnings FAQ
Can you provide the last earnings date for NOVABAY PHARMACEUTICALS INC?
NOVABAY PHARMACEUTICALS INC (NBY) last reported earnings on 11/5/2025.
Can you provide information on whether NOVABAY PHARMACEUTICALS INC beat earnings estimates in the last quarter?
NOVABAY PHARMACEUTICALS INC (NBY) missed EPS estimates and missed revenue estimates in the most recent quarter.